IHS Reaches New 52-Week High (IHS)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- IHS (NYSE: IHS) hit a new 52-week high Thursday as it is currently trading at $112.33, above its previous 52-week high of $112.22 with 73,314 shares traded as of 1:14 p.m. ET. Average volume has been 425,600 shares over the past 30 days.

IHS has a market cap of $7.26 billion and is part of the technology sector and computer software & services industry. Shares are up 29% year to date as of the close of trading on Wednesday.

IHS Inc. provides critical information and insight products and services. The company has a P/E ratio of 55.7, above the average computer software & services industry P/E ratio of 54.9 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates IHS as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full IHS Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing